Suppr超能文献

α1-肾上腺素能受体拮抗作用增强L-NAME诱导的全身和肾血管收缩反应。

Potentiation of L-NAME-induced systemic and renal vasoconstrictor responses by alpha1-adrenoceptor antagonism.

作者信息

van der Linde Nicole Aj, Boomsma Frans, van den Meiracker Anton H

机构信息

Erasmus MC, Department of Vascular and Metabolic Diseases, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

出版信息

J Hypertens. 2005 May;23(5):1017-24. doi: 10.1097/01.hjh.0000166843.42227.92.

Abstract

BACKGROUND

Acute inhibition of nitric oxide synthase results in systemic and renal vasoconstriction, which might be attributable to unopposed activity of the sympathetic nervous (SNS) and the renin-angiotensin system (RAS). We studied the effects of N-nitro-L-arginine methyl ester (L-NAME) during alpha1-adrenoceptor blockade and concomitant angiotensin II type 1 (AT1)-receptor blockade in hypertensive individuals pretreated with hydrochlorothiazide (Hct; 25 mg once daily).

METHODS

Thirteen individuals (47 +/- 9 years) were studied during administration of placebo, and after pretreatment with Hct + doxazosin (Dox; 8 mg twice daily for 9 days), with Hct + Dox + losartan (Los; 50 mg twice daily for 9 days), or (n = 5) with doxazosin or Dox + Los without hydrochlorothiazide. Mean arterial pressure (MAP) and cardiac output were derived from the finger blood pressure signal recorded by Finapres. Systemic vascular resistance (SVR) was calculated as MAP/cardiac output. Five renal clearance studies of 40 min were performed. Renal vascular resistance (RVR) was calculated as MAP divided by renal blood flow (RBF). L-NAME (12.5 microg/kg per min intravenously) was given during the third clearance period.

RESULTS

MAP was 113 +/- 11 mmHg at baseline and decreased to 99 +/- 10 mmHg during the administration of Hct + Dox and to 92 +/- 10 mmHg during Hct + Dox + Los. This decrease in MAP was caused by a decrease in SVR (P = 0.0009). Pretreatment with Hct + Dox or Hct + Dox + Los had no effect on glomerular filtration rate or RBF. Infusion of L-NAME during the administration of Hct + Dox resulted in an augmented (P < 0.0001) increase in MAP (18%), SVR (61%) and RVR (70%) compared with those observed with placebo (8, 30 and 49%, respectively). This augmentation was abolished by losartan.

CONCLUSION

L-NAME-induced systemic and renal vasoconstrictor responses are potentiated during alpha1-adrenoceptor blockade. This potentiation was abolished by AT1-receptor antagonism. In man, unopposed activity of the SNS or SNS and RAS is not involved in the systemic and renal vasoconstriction induced by L-NAME.

摘要

背景

一氧化氮合酶的急性抑制会导致全身和肾血管收缩,这可能归因于交感神经(SNS)和肾素 - 血管紧张素系统(RAS)的无对抗活性。我们研究了在接受氢氯噻嗪(Hct;每日一次,25 mg)预处理的高血压个体中,N - 硝基 - L - 精氨酸甲酯(L - NAME)在α1 - 肾上腺素能受体阻断及同时进行的1型血管紧张素II(AT1)受体阻断期间的作用。

方法

对13名个体(47±9岁)进行研究,分别给予安慰剂,以及用Hct + 多沙唑嗪(Dox;每日两次,8 mg,共9天)、Hct + Dox + 氯沙坦(Los;每日两次,50 mg,共9天)预处理后,或(n = 5)给予多沙唑嗪或Dox + Los但不用氢氯噻嗪。平均动脉压(MAP)和心输出量由Finapres记录的手指血压信号得出。全身血管阻力(SVR)计算为MAP/心输出量。进行了5次40分钟的肾清除率研究。肾血管阻力(RVR)计算为MAP除以肾血流量(RBF)。在第三个清除期静脉给予L - NAME(每分钟12.5μg/kg)。

结果

基线时MAP为113±11 mmHg,在给予Hct + Dox期间降至99±10 mmHg,在Hct + Dox + Los期间降至92±10 mmHg。MAP的这种降低是由SVR降低引起的(P = 0.0009)。用Hct + Dox或Hct + Dox + Los预处理对肾小球滤过率或RBF无影响。在给予Hct + Dox期间输注L - NAME导致MAP(18%)、SVR(61%)和RVR(70%)的增加幅度比安慰剂组观察到的更大(分别为8%、30%和49%,P < 0.0001)。氯沙坦消除了这种增强作用。

结论

L - NAME诱导全身和肾血管收缩反应在α1 - 肾上腺素能受体阻断期间增强。这种增强作用被AT1受体拮抗所消除。在人类中,SNS或SNS和RAS的无对抗活性不参与L - NAME诱导的全身和肾血管收缩。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验